89bio (ETNB) Buyback Yield % : -26.68 (As of May. 31, 2024)

View and export this data going back to 2019. Start your Free Trial

What is 89bio Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

89bio's current buyback yield was -26.68%.

89bio Buyback Yield % Historical Data

The historical data trend for 89bio's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

89bio Buyback Yield % Chart

89bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buyback Yield %

Get a 7-Day Free Trial

-24.19

-32.46

-1.42

-18.18

-47.66

89bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Buyback Yield %	Get a 7-Day Free Trial															-111.82	-6.76	0.18	-62.45	-7.60

Competitive Comparison of 89bio's Buyback Yield %

For the Biotechnology subindustry, 89bio's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

89bio's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 89bio's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where 89bio's Buyback Yield % falls into.

89bio Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

89bio's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	496.565)	/	1041.819198
	=	-47.66%

89bio's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	21.067)	*	4	/	1108.124508
	=	-7.60%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.

89bio Buyback Yield % Related Terms

Thank you for viewing the detailed overview of 89bio's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

89bio (ETNB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 89bio Inc (NAS:ETNB) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

142 Sansome Street, Second Floor, San Francisco, CA, USA, 94104

Website

https://www.89bio.com

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Executives

Kathleen Laporte	director
Rohan Palekar	director, officer: Chief Executive Officer	201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Atkinson Edward Morrow Iii	director	C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Quoc Le-nguyen	officer: See Remarks	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Ryan Martins	officer: Chief Financial Officer	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Michael R Hayden	director	C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ram Waisbourd	officer: See Remarks	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Gregory Grunberg	director, 10 percent owner	100 BEAVER STREET, WALTHAM MA 02453
Anat Naschitz	director, 10 percent owner	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
Steven Altschuler	director	MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026